40 related articles for article (PubMed ID: 11488934)
1. The optimal dose of arsenic trioxide induced opposite efficacy in autophagy between K562 cells and their initiating cells to eradicate human myelogenous leukemia.
Guo Z; Meng M; Geng S; Du Z; Zheng Y; Yao J; Li Z; Han G; Lin H; Du G
J Ethnopharmacol; 2017 Jan; 196():29-38. PubMed ID: 27965050
[TBL] [Abstract][Full Text] [Related]
2. Multifactorial Modes of Action of Arsenic Trioxide in Cancer Cells as Analyzed by Classical and Network Pharmacology.
Dawood M; Hamdoun S; Efferth T
Front Pharmacol; 2018; 9():143. PubMed ID: 29535630
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 1,2,4-thiadiazolidine-3,5-dione analogs that exhibit unusual and selective rapid cell death kinetics against acute myelogenous leukemia cells in culture.
Nasim S; Guzman ML; Jordan CT; Crooks PA
Bioorg Med Chem Lett; 2011 Aug; 21(16):4879-83. PubMed ID: 21757349
[TBL] [Abstract][Full Text] [Related]
4. Corrigendum to "The optimal dose of arsenic trioxide induced opposite efficacy in autophagy between K562 cells and their initiating cells to eradicate human myelogenous leukemia" [J. Ethnopharmacol. 196 (2017) 29-38].
Guo Z; Meng M; Geng S; Du Z; Zheng Y; Yao J; Li Z; Han G; Lin H; Du G
J Ethnopharmacol; 2024 Jan; 319(Pt 1):117391. PubMed ID: 37945443
[No Abstract] [Full Text] [Related]
5. Single Specific Primer-Polymerase Chain Reaction (SSP-PCR) and Genome Walking.
Shyamala V; Ferro-Luzzi Ames G
Methods Mol Biol; 1993; 15():339-48. PubMed ID: 21400290
[TBL] [Abstract][Full Text] [Related]
6. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients.
Shen ZX; Chen GQ; Ni JH; Li XS; Xiong SM; Qiu QY; Zhu J; Tang W; Sun GL; Yang KQ; Chen Y; Zhou L; Fang ZW; Wang YT; Ma J; Zhang P; Zhang TD; Chen SJ; Chen Z; Wang ZY
Blood; 1997 May; 89(9):3354-60. PubMed ID: 9129042
[TBL] [Abstract][Full Text] [Related]
7. Circular RNAs: Potential Regulators of Treatment Resistance in Human Cancers.
Jeyaraman S; Hanif EAM; Ab Mutalib NS; Jamal R; Abu N
Front Genet; 2019; 10():1369. PubMed ID: 32047511
[TBL] [Abstract][Full Text] [Related]
8. Factors determining sensitivity and resistance of tumor cells to arsenic trioxide.
Sertel S; Tome M; Briehl MM; Bauer J; Hock K; Plinkert PK; Efferth T
PLoS One; 2012; 7(5):e35584. PubMed ID: 22590507
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide and ascorbic acid demonstrate promising activity against primary human CLL cells in vitro.
Biswas S; Zhao X; Mone AP; Mo X; Vargo M; Jarjoura D; Byrd JC; Muthusamy N
Leuk Res; 2010 Jul; 34(7):925-31. PubMed ID: 20171736
[TBL] [Abstract][Full Text] [Related]
10. Targeting signal transducer and activator of transcription signaling pathway in leukemias.
Benekli M; Baumann H; Wetzler M
J Clin Oncol; 2009 Sep; 27(26):4422-32. PubMed ID: 19667270
[TBL] [Abstract][Full Text] [Related]
11. Arsenic trioxide affects signal transducer and activator of transcription proteins through alteration of protein tyrosine kinase phosphorylation.
Wetzler M; Brady MT; Tracy E; Li ZR; Donohue KA; O'Loughlin KL; Cheng Y; Mortazavi A; McDonald AA; Kunapuli P; Wallace PK; Baer MR; Cowell JK; Baumann H
Clin Cancer Res; 2006 Nov; 12(22):6817-25. PubMed ID: 17121903
[TBL] [Abstract][Full Text] [Related]
12. As(2)O(3) enhances retroviral reverse transcription and counteracts Ref1 antiviral activity.
Berthoux L; Towers GJ; Gurer C; Salomoni P; Pandolfi PP; Luban J
J Virol; 2003 Mar; 77(5):3167-80. PubMed ID: 12584341
[TBL] [Abstract][Full Text] [Related]
13. The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms.
Zhang W; Ohnishi K; Shigeno K; Fujisawa S; Naito K; Nakamura S; Takeshita K; Takeshita A; Ohno R
Leukemia; 1998 Sep; 12(9):1383-91. PubMed ID: 9737686
[TBL] [Abstract][Full Text] [Related]
14. Catalase activity and arsenic sensitivity in acute leukemia.
Coe E; Schimmer AD
Leuk Lymphoma; 2008 Oct; 49(10):1976-81. PubMed ID: 18949620
[TBL] [Abstract][Full Text] [Related]
15. Dual effects of arsenic trioxide (As2O3) on non-acute promyelocytic leukaemia myeloid cell lines: induction of apoptosis and inhibition of proliferation.
Rojewski MT; Baldus C; Knauf W; Thiel E; Schrezenmeier H
Br J Haematol; 2002 Mar; 116(3):555-63. PubMed ID: 11849211
[TBL] [Abstract][Full Text] [Related]
16. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.
Huan SY; Yang CH; Chen YC
Leuk Lymphoma; 2000 Jul; 38(3-4):283-93. PubMed ID: 10830735
[TBL] [Abstract][Full Text] [Related]
17. The effects of arsenic trioxide (As2O3) on human megakaryocytic leukemia cell lines. With a comparison of its effects on other cell lineages.
Alemany M; Levin J
Leuk Lymphoma; 2000 Jun; 38(1-2):153-63. PubMed ID: 10811458
[TBL] [Abstract][Full Text] [Related]
18. Effects of arsenic trioxide (As2O3) on leukemic cells from patients with non-M3 acute myelogenous leukemia: studies of cytotoxicity, apoptosis and the pattern of resistance.
Lehmann S; Bengtzen S; Paul A; Christensson B; Paul C
Eur J Haematol; 2001 Jun; 66(6):357-64. PubMed ID: 11488934
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
